Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

Learn more about:
Related Clinical Trial
Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors Early Integration of Supportive Care Into Standard Oncology Care for Metastatic Uveal Melanoma Patients Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal Melanoma Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma A Prospective Natural History Study in Uveal Melanoma Uveal Melanoma and Brachytheraphy: Long-term Outcomes. A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas Study to Evaluate the Safety of IMM-01 in Patients With Advanced Solid Tumours Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME) Phase 2 Trial of AU-011 Via Suprachoroidal Administration With a Dose Escalation and Randomized, Masked Dose Expansion Designed to Evaluate Safety and Efficacy of AU-011 in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery A Study of PLX2853 in Advanced Malignancies. Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519) Treatment Of Radiation Retinopathy Trial Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Study in Subjects With Small Primary Choroidal Melanoma Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination Trial of AEB071 in Combination With BYL719 in Patients With Melanoma Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF Vorinostat in Treating Patients With Metastatic Melanoma of the Eye Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases 5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma Pembrolizumab in Treating Patients With Advanced Uveal Melanoma Vascular Response to Brachytherapy Using Functional OCT Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma Endoresection of the Tumor Scar or Transpupillary Thermotherapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser) Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER) Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma New Biopsy Technique for Uveal Melanoma Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy Intermittent Selumetinib for Uveal Melanoma Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0) Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma Vorinostat in Patients With Class 2 High Risk Uveal Melanoma Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases A Phase II Study of BVD-523 in Metastatic Uveal Melanoma Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma Treatment With Intravitreal Avastin for Large Uveal Melanomas

Brief Title

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

Official Title

A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination With GSK2141795 in Patients With Advanced Uveal Melanoma

Brief Summary

      This randomized phase II trial studies how well trametinib with or without Akt inhibitor
      GSK2141795 (GSK2141795) works in treating patients with uveal melanoma that has spread to
      other parts of the body (metastatic). Trametinib and GSK2141795 may stop the growth of tumor
      cells by blocking some of the enzymes needed for cell growth. It is not yet known whether
      trametinib is more effective with or without GSK2141795 in treating patients with metastatic
      uveal melanoma.
    

Detailed Description

      PRIMARY OBJECTIVES:

      I. To compare progression-free survival between those treated with trametinib alone and those
      treated with the combination of trametinib and GSK2141795.

      SECONDARY OBJECTIVES:

      I. To compare overall survival between those treated with trametinib alone and those treated
      with the combination of trametinib and GSK2141795.

      II. To compare the overall response rate between those treated with trametinib alone and
      those treated with the combination of trametinib and GSK2141795.

      III. To compare the safety and toxicity between those treated with trametinib alone and those
      treated with the combination of trametinib and GSK2141795.

      TERTIARY OBJECTIVES:

      I. To assess clinical outcomes (response rate, progression-free and overall survival) with
      trametinib and GSK2141795 after progression on trametinib.

      II. To assess toxicity with trametinib and GSK2141795 after progression on trametinib.

      III. To correlate clinical outcome with Gnaq/11 mutational status. IV. To assess the
      pharmacodynamic effects of trametinib alone and with GSK2141795, and utilize
      whole-transcriptome and reverse phase protein array to identify markers of sensitivity and
      primary resistance to trametinib alone and with GSK2141795.

      V. To assess for changes in circulating tumor deoxyribonucleic acid (DNA) with therapy.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM A: Patients receive trametinib orally (PO) once daily (QD) on days 1-28. Courses repeat
      every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients who
      experience objective disease progression may crossover to Arm B. (no patients will be
      enrolled to Arm B or Crossover therapy as of 11/6/2015)

      ARM B: Patients receive trametinib PO QD and Akt inhibitor GSK2141795 PO QD on days 1-28.
      Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up for 4 weeks and then every 12
      weeks thereafter.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Time to Progression (Progression-free Survival [PFS]), Defined From the Date of Randomization to the Date of Documented Progression or Death Per RECIST

Secondary Outcome

 Number of Participants With Toxicity, Graded According to the National Cancer Institute CTCAE v4.0, Who Were Treated and Did Not Withdraw Consent

Condition

Recurrent Uveal Melanoma

Intervention

Laboratory Biomarker Analysis

Study Arms / Comparison Groups

 Arm A (trametinib)
Description:  Patients receive trametinib PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients who experience objective disease progression may crossover to Arm B. (no patients will be enrolled to Arm B or Crossover therapy as of 11/6/2015)

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Other

Estimated Enrollment

42

Start Date

October 23, 2013

Completion Date

September 1, 2017

Primary Completion Date

September 1, 2017

Eligibility Criteria

        Inclusion Criteria:

          -  Patients must have metastatic histologically or cytologically confirmed uveal
             melanoma; if histologic or cytologic confirmation of the primary is not available,
             confirmation of the primary diagnosis of uveal melanoma by the treating investigator
             can be clinically obtained, as per standard practice for uveal melanoma; pathologic
             confirmation of metastatic disease will be performed at Memorial Sloan Kettering (MSK)
             or at a participating site

          -  Patients must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded) as >=
             20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT)
             scan

          -  Patients may not have received prior systemic or hepatic directed
             infusional/embolization therapies for advanced uveal melanoma; local therapies such as
             radiofrequency ablation or cryotherapy for metastatic disease are permitted but must
             have been performed at least 21 days prior to initiation of study therapy; lesions
             treated with local modalities such as radiofrequency ablation or cryotherapy may not
             be used as target lesions unless they demonstrate growth over a minimum of 3 months on
             subsequent imaging studies

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)

          -  Life expectancy of greater than 3 months

          -  Able to swallow and retain orally-administered medication and does not have any
             clinically significant gastrointestinal abnormalities that may alter absorption such
             as malabsorption syndrome or major resection of the stomach or bowels

          -  All prior treatment-related toxicities must be Common Terminology Criteria for Adverse
             Events (CTCAE) version (v)4 grade =< 1 (except alopecia) at the time of randomization
             and crossover

          -  Leukocytes >= 3,000/mcL

          -  Absolute neutrophil count >= 1,500/mcL

          -  Platelets >= 100,000/mcL

          -  Hemoglobin >= 9.0 g/dL (not requiring transfusions within the past 2 weeks)

          -  Total bilirubin =< 1.5 x institutional upper limit of normal; Note: patients with
             hyperbilirubinemia clinically consistent with an inherited disorder of bilirubin
             metabolism (e.g., Gilbert syndrome) will be eligible at the discretion of the treating
             physician and/or the principal investigator

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =< 1.5 x institutional upper limit of normal for patients with no concurrent liver
             metastases, OR =< 2.5 x institutional upper limit of normal for patients with
             concurrent liver metastases

          -  Creatinine =< 1.5 mg/dL OR calculated creatinine clearance (Cockcroft-Gault formula)
             >= 50 mL/min OR 24-hour urine creatinine clearance >= 50 mL/min

          -  Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by
             echocardiogram (ECHO) or multigated acquisition scan (MUGA)

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for
             the duration of study participation; women of child-bearing potential must have a
             negative blood pregnancy test within 14 days prior to start of protocol treatment;
             should a woman become pregnant or suspect she is pregnant while she or her partner is
             participating in this study, she should inform her treating physician immediately; men
             treated or enrolled on this protocol must also agree to use adequate contraception
             prior to the study, for the duration of study participation, and 4 months after
             completion of trametinib administration

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Patients must agree to provide all imaging studies for central radiology review; this
             central radiology review may be performed retrospectively and will not be utilized for
             decision making for patients on study

          -  ELIGIBILITY CRITERIA FOR CROSSOVER REGISTRATION

          -  Previously treated with trametinib on Arm A and experienced objective disease
             progression by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

          -  Not removed from trametinib treatment due to the development of unacceptable toxicity
             that is not manageable with dose reduction

          -  No other drug treatment for malignant melanoma administered after completing study
             treatment with trametinib

          -  Meet all eligibility criteria with the exception of:

               -  Prior therapy with trametinib will be permitted

               -  All laboratory parameters must be met as outlined except for ALT and total
                  bilirubin, which must meet criteria for continued therapy

               -  Patients who are eligible for cross-over will not need to undergo another
                  ophthalmologic examination

        Exclusion Criteria:

          -  History of another malignancy except for those who have been disease-free for 3 years,
             or patients with a history of completely resected non-melanoma skin cancer and/or
             patients with indolent secondary malignancies not requiring active therapy, are
             eligible; consult the study MSK Principal Investigator or the Cancer Therapy
             Evaluation Program (CTEP) Medical Monitor if unsure whether second malignancies meet
             the requirements specified above

          -  History of interstitial lung disease or pneumonitis

          -  Any major surgery or extensive radiotherapy within 21 days prior to randomization and
             crossover

          -  Use of other investigational drugs within 28 days (or five half-lives, whichever is
             shorter; with a minimum of 14 days from the last dose) preceding the first dose of
             trametinib alone or with GSK2141795 and during the study

          -  Symptomatic or untreated leptomeningeal or brain metastases or spinal cord
             compression; treated brain metastases must have been stable for at least 1 month

          -  Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to trametinib, GSK2141795, or excipients or to dimethyl sulfoxide
             (DMSO)

          -  Current use of a prohibited medication

          -  History or current evidence/risk of retinal vein occlusion (RVO) or retinal pigment
             epithelial detachment (RPED) in the eye unaffected by uveal melanoma

          -  Patients with abnormal fasting glucose values (values > upper limit of normal [ULN] or
             < LLN) at screening will be excluded; in addition, patients with type 1 diabetes will
             also be excluded; however, patients with type 2 diabetes will be allowed if diagnosed
             >= 6 months prior to enrollment, and if presenting with a normal fasting glucose value
             and a regular hemoglobin A1C (HbA1C) =< 8% at screening

          -  History or evidence of cardiovascular risk including any of the following:

               -  Left ventricular ejection fraction (LVEF) < LLN

               -  A QT interval corrected for heart rate using the Bazett's formula QTcB >= 480
                  msec

               -  History or evidence of current clinically significant uncontrolled arrhythmias
                  (exception: patients with controlled atrial fibrillation for > 30 days prior to
                  randomization are eligible)

               -  History of acute coronary syndromes (including myocardial infarction and unstable
                  angina), coronary angioplasty, or stenting within 6 months prior to randomization

               -  History or evidence of current >= class II congestive heart failure as defined by
                  the New York Heart Association (NYHA) functional classification system

               -  Treatment-refractory hypertension defined as a blood pressure of systolic > 140
                  mmHg and/or diastolic > 90 mmHg which cannot be controlled by anti-hypertensive
                  therapy

               -  Patients with intra-cardiac defibrillators

               -  Known cardiac metastases

          -  Known hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (patients with
             chronic or cleared HBV and HCV infection are eligible); patients with human
             immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  The study drug must not be administered to pregnant women or nursing mothers; women of
             childbearing potential should be advised to avoid pregnancy and use effective methods
             of contraception; men with a female partner of childbearing potential must have either
             had a prior vasectomy or agree to use effective contraception; if a female patient or
             a female partner of a patient becomes pregnant while the patient receives trametinib,
             the potential hazard to the fetus should be explained to the patient and partner (as
             applicable)
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Alexander Shoushtari, , 

Location Countries

France

Location Countries

France

Administrative Informations


NCT ID

NCT01979523

Organization ID

NCI-2013-02091

Secondary IDs

NCI-2013-02091

Responsible Party

Sponsor

Study Sponsor

National Cancer Institute (NCI)


Study Sponsor

Alexander Shoushtari, Principal Investigator, Memorial Sloan Kettering Cancer Center


Verification Date

February 2020